Marshall Wace’s CareMax, Inc. Class A Common Stock CMAX Stock Holding History

Marshall Wace’s Portfolio CMAX Stock Details CMAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-164	Closed	-$38K	–	4417
2021 Q4	$38K	Buy	+164	New	+$39K	﹤0.01%	3615
2021 Q2	–	Sell	-379	Closed	-$138K	–	3536
2021 Q1	$138K	Buy	+379	New	+$160K	﹤0.01%	2324

Other funds holding CMAX

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Marshall Wace's CMAX Position: Q1 2022 in Review

Marshall Wace sold out of CareMax, Inc. Class A Common Stock (CMAX) in Q1 2022, closing a stake of 164 shares — an estimated $38K sold.

Marshall Wace first reported a position in CMAX in Q1 2021 and held it in 2 quarters. The position peaked at $138K in Q1 2021. 51 funds tracked by Wall St. Rank hold CMAX as of Q1 2022.

Marshall Wace reported no remaining CareMax, Inc. Class A Common Stock position as of Q1 2022 after selling out during the quarter.
Marshall Wace sold 164 CareMax, Inc. Class A Common Stock shares in Q1 2022, an estimated $38K.
Marshall Wace first reported a position in CareMax, Inc. Class A Common Stock in Q1 2021 and held it in 2 quarters.
Marshall Wace's CareMax, Inc. Class A Common Stock position peaked at $138K in Q1 2021.
51 funds tracked by Wall St. Rank held CareMax, Inc. Class A Common Stock as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.